Moreover, we revealed that ACT001, a guaianolide sesquiterpene lactones undergoing phase II clinical trial for GBM therapy in America and China has received American and European orphan drug qualifications for the prominent effect, targeted lung cancer stem cells by binding and inducing Olig2 ubiquitination degradation. The gene discussed is OLIG2; the disease is lung carcinoma.